A citation-based method for searching scientific literature

Suk Chon, Jean François Gautier. Diabetes Metab J 2016
Times Cited: 30







List of co-cited articles
125 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
16

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
D R Matthews, J P Hosker, A S Rudenski, B A Naylor, D F Treacher, R C Turner. Diabetologia 1985
13

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
13

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
13

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
10


Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E Kahn, Steven M Haffner, Mark A Heise, William H Herman, Rury R Holman, Nigel P Jones, Barbara G Kravitz, John M Lachin, M Colleen O'Neill, Bernard Zinman,[...]. N Engl J Med 2006
10

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
10


Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi,[...]. Diabetes Metab J 2016
9
33


Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
731
10


Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.
Angus G Jones, Timothy J McDonald, Beverley M Shields, Anita V Hill, Christopher J Hyde, Bridget A Knight, Andrew T Hattersley. Diabetes Care 2016
73
10

Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis.
Jacqueline A Koehler, Laurie L Baggio, Xiemin Cao, Tahmid Abdulla, Jonathan E Campbell, Thomas Secher, Jacob Jelsing, Brett Larsen, Daniel J Drucker. Diabetes 2015
38
10



Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
W Kothny, J Foley, P Kozlovski, Q Shao, B Gallwitz, V Lukashevich. Diabetes Obes Metab 2013
80
10

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca,[...]. Endocr Pract 2017
271
10


Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Alexandra E Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A Rizza, Peter C Butler. Diabetes 2003
10


Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
10

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
M A Nauck, I Vardarli, C F Deacon, J J Holst, J J Meier. Diabetologia 2011
301
10

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Jae Min Cho, Hye Won Jang, Hwanju Cheon, Yeon Taek Jeong, Do-Hoon Kim, Yu-Mi Lim, Song-Hyen Choi, Eun-Kyoung Yang, Chang-Yell Shin, Moon Ho Son,[...]. Diabetes Res Clin Pract 2011
40
6

Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Katsutoshi Miyagawa, Tatsuya Kondo, Rieko Goto, Rina Matsuyama, Kaoru Ono, Sayaka Kitano, Shuji Kawasaki, Motoyuki Igata, Junji Kawashima, Takeshi Matsumura,[...]. Cardiovasc Diabetol 2013
23
8

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Namyi Gu, Min Kyu Park, Tae-Eun Kim, Mi Young Bahng, Kyoung Soo Lim, Sang-Heon Cho, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang, Kyung-Sang Yu. Drug Des Devel Ther 2014
28
7

Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.
Hiromichi Murase, Atsushi Kuno, Takayuki Miki, Masaya Tanno, Toshiyuki Yano, Hidemichi Kouzu, Satoko Ishikawa, Toshiyuki Tobisawa, Makoto Ogasawara, Keitaro Nishizawa,[...]. Cardiovasc Diabetol 2015
39
6

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Wei Jing Liu, Shu Hua Xie, Yu Ning Liu, Won Kim, Heung Yong Jin, Sung Kwang Park, Yi Ming Shao, Tae Sun Park. J Pharmacol Exp Ther 2012
161
6

The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
Payal Shah, Amin Ardestani, Gitanjali Dharmadhikari, Svenja Laue, Desiree M Schumann, Julie Kerr-Conte, Francois Pattou, Thomas Klein, Kathrin Maedler. J Clin Endocrinol Metab 2013
64
6

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Kazufumi Nakamura, Hiroki Oe, Hajime Kihara, Kenei Shimada, Shota Fukuda, Kyoko Watanabe, Tsutomu Takagi, Kei Yunoki, Toru Miyoshi, Kumiko Hirata,[...]. Cardiovasc Diabetol 2014
84
6


Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Makoto Ayaori, Naotsugu Iwakami, Harumi Uto-Kondo, Hiroki Sato, Makoto Sasaki, Tomohiro Komatsu, Maki Iizuka, Shunichi Takiguchi, Emi Yakushiji, Kazuhiro Nakaya,[...]. J Am Heart Assoc 2013
88
6

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Thomas Karagiannis, Paschalis Paschos, Konstantinos Paletas, David R Matthews, Apostolos Tsapas. BMJ 2012
278
6

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Annalisa Capuano, Liberata Sportiello, Maria Ida Maiorino, Francesco Rossi, Dario Giugliano, Katherine Esposito. Drug Des Devel Ther 2013
32
6


Exendin-4 modulates diabetes onset in nonobese diabetic mice.
Irene Hadjiyanni, Laurie L Baggio, Philippe Poussier, Daniel J Drucker. Endocrinology 2008
79
6

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
Elizabeth R Seaquist, John Anderson, Belinda Childs, Philip Cryer, Samuel Dagogo-Jack, Lisa Fish, Simon R Heller, Henry Rodriguez, James Rosenzweig, Robert Vigersky. Diabetes Care 2013
756
6




Distinct differences in the responses of the human pancreatic β-cell line EndoC-βH1 and human islets to proinflammatory cytokines.
Bryndon J Oleson, Jennifer A McGraw, Katarzyna A Broniowska, Mani Annamalai, Jing Chen, Justin R Bushkofsky, Dawn B Davis, John A Corbett, Clayton E Mathews. Am J Physiol Regul Integr Comp Physiol 2015
22
9

Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy.
Marcela Brissova, Michael J Fowler, Wendell E Nicholson, Anita Chu, Boaz Hirshberg, David M Harlan, Alvin C Powers. J Histochem Cytochem 2005
465
6

Pancreatic beta cell lines and their applications in diabetes mellitus research.
Masa Skelin, Marjan Rupnik, Avrelija Cencic. ALTEX 2010
143
6

Impact of islet architecture on β-cell heterogeneity, plasticity and function.
Sara S Roscioni, Adriana Migliorini, Moritz Gegg, Heiko Lickert. Nat Rev Endocrinol 2016
86
6

The unique cytoarchitecture of human pancreatic islets has implications for islet cell function.
Over Cabrera, Dora M Berman, Norma S Kenyon, Camillo Ricordi, Per-Olof Berggren, Alejandro Caicedo. Proc Natl Acad Sci U S A 2006
717
6

A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion.
Philippe Ravassard, Yasmine Hazhouz, Séverine Pechberty, Emilie Bricout-Neveu, Mathieu Armanet, Paul Czernichow, Raphael Scharfmann. J Clin Invest 2011
304
6


Pancreatic β-Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes.
Tehila Dahan, Oren Ziv, Elad Horwitz, Hai Zemmour, Judith Lavi, Avital Swisa, Gil Leibowitz, Frances M Ashcroft, Peter In't Veld, Benjamin Glaser,[...]. Diabetes 2017
29
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.